000 01488 a2200361 4500
005 20250516233426.0
264 0 _c20150320
008 201503s 0 0 eng d
022 _a1527-7755
024 7 _a10.1200/JCO.2014.56.2017
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aValcamonico, Francesca
245 0 0 _aIs time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?
_h[electronic resource]
260 _bJournal of clinical oncology : official journal of the American Society of Clinical Oncology
_cNov 2014
300 _a3684-5 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aAdenocarcinoma
_xdrug therapy
650 0 4 _aBone Density Conservation Agents
_xtherapeutic use
650 0 4 _aBone Neoplasms
_xdrug therapy
650 0 4 _aDiphosphonates
_xtherapeutic use
650 0 4 _aHumans
650 0 4 _aImidazoles
_xtherapeutic use
650 0 4 _aMale
650 0 4 _aProstatic Neoplasms
_xdrug therapy
700 1 _aPetrelli, Fausto
700 1 _aFerrari, Laura
700 1 _aFerrari, Vittorio
700 1 _aGrisanti, Salvatore
700 1 _aBarni, Sandro
700 1 _aBerruti, Alfredo
773 0 _tJournal of clinical oncology : official journal of the American Society of Clinical Oncology
_gvol. 32
_gno. 32
_gp. 3684-5
856 4 0 _uhttps://doi.org/10.1200/JCO.2014.56.2017
_zAvailable from publisher's website
999 _c24194531
_d24194531